The Global Kidney Cancer Drugs Market is Driven by Growing Prevalence of Kidney Cancer
Kidney cancer drugs are medications that are used in the treatment of kidney cancer. Some common kidney cancer drugs include immunotherapy drugs, targeted therapy drugs, and chemotherapy drugs. Immunotherapy drugs help boost the body's natural defenses to fight kidney cancer. Targeted therapy drugs specifically target the changes in cancer cells that help them grow and spread. Chemotherapy drugs are powerful medications that destroy fast-growing cancer cells. Kidney cancer drugs have significantly improved survival rates and quality of life for patients with kidney cancer. Advances in targeted therapy have expanded treatment options and reduced side effects compared to traditional chemotherapy.
The Global Kidney Cancer Drugs Market is estimated to be valued at US$ 7.15 Bn in 2024 and is expected to exhibit a CAGR of 9.7% over the forecast period from 2024 to 2031.
Key Takeaways
Key players operating in the Kidney Cancer Drugs market are Celanese Corporation, British Petroleum, Eastman Chemical Company, Jiangsu Sopo (Group) Co., Ltd., China Petroleum & Chemical Corporation (Sinopec), Lyondell Basell Industries, Saudi Basic Industries Corporation (SABIC), Mitsubishi Chemical Company, PetroChina Co. Ltd., PetroChina Co. Ltd., BASF SE. These players are focusing on developing advanced kidney cancer drugs to improve treatment outcomes.
The increasing incidence and prevalence of Kidney Cancer Drugs Market Demand globally is expected to drive the demand for effective kidney cancer drugs during the forecast period. According to the American Cancer Society, nearly 76,000 new cases of kidney cancer are diagnosed in the United States each year.
The major players are expanding their presence in developing countries to tap the growth opportunities offered by these emerging markets. The improving healthcare infrastructure and increasing healthcare spending in developing nations will further support the global expansion of the kidney cancer drugs market.
Market Drivers
The growing prevalence of obesity and smoking are significant risk factors attributable to the increasing incidence of kidney cancer worldwide. According to the WHO, globally over 1.9 billion adults were overweight in 2016, of which over 650 million were obese. Obesity has been strongly associated with kidney cancer. Thus, the rising obesity rates are expected to drive the kidney cancer drugs market.
Get more insights on This Topic- Kidney Cancer Drugs Market
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian